Tagged with Americas

Dominican Republic Alejandro Paolini, Siemens Healthineers’ managing director for Mexico, Central America and Caribbean, dives into the medical technology industry’s business model transformation, switching from selling products to services with a risk-sharing approach. In addition, he reflects on the impact of the pandemic on the company’s performance, their unique presence in Central…

LatAm Medtronic’s VP for North Latin America, Héctor Orellana, outlines the largest company’s new vision for that region, their efforts and challenges to continue gaining market access, and explains why the company is not shying away from Central America but rather doubling down.   The region represents a great opportunity to…

LatAm Writing in the April edition of DIA’s Global Forum magazine, Maria Cristina Mota Pina of Abbvie on behalf of FIFARMA Regulatory & Biologics Working Group highlights the significance of regulatory reliance between regulators in the LatAm and Caribbean region and proposes how it can be strengthened.   Regulatory reliance is…

Americas The latest LatAm pharma news, including COVID-19 vaccine rollouts in Colombia, Brazil, and Mexico as well as legal and regulatory updates on the status of medical cannabis in the region.   COVAX initiative begins in Latin America with 117,000 Pfizer vaccine doses for Colombia (Spanish) https://elpais.com/sociedad/2021-03-01/la-iniciativa-covax-debuta-en-america-latina-con-117000-vacunas-para-colombia.html   At least 13…

Dominican Republic Genald Senior, general manager for Leterago, the leading pharma distributor in the Dominican Republic, discusses how the company has managed to control over a fifth of the market, the country’s regulatory environment, the challenges of getting to the 1,800 pharmacies in the country, and their pandemic journey.   Technology will…

Americas Writing in the March edition of DIA’s Global Forum magazine, EMD Serono’s Ana Padua outlines the findings of a recent study into accelerated regulatory pathways in Latin America which aim to reduce approval timelines for innovative medicines.   The Latin America region offers a number of registration pathways to accelerate…

Dominican Republic Alejandro Mora, Ferrer’s country manager for Central America & Caribbean, discusses the complexity of the region’s healthcare systems, the company’s strategy to compete against local players, and the importance for multinational companies of going beyond the pill in the region, making efforts to be sustainable and help the environment.  …

Dominican Republic The Association of Representatives, Agents and Pharmaceutical Producers (ARAPF), represents 65 companies in the Dominican Republic, including big pharma companies like Pfizer, Bayer, Roche, GSK, Nestlé, Sanofi and Novartis. Its president, Henry Suárez, reflects on the impact of the COVID-19 pandemic, the country’s objective to expand its social security system…

Americas The Top 15 pharmaceutical companies in the Central America and Caribbean (CENCA) market list is dominated by familiar big pharma players. However, among the liked of Sanofi, Abbott, Bayer, Pfizer, AstraZeneca, and Novartis sits Megalabs – a Latin American player that has been able to establish itself as a regional…

Americas The Top 15 pharma companies in the Central America & Caribbean (CENCA) region’s retail market (Rx & OTC) for 2019 ranked by sales in USD millions. US-headquartered Abbott tops the list, followed by Uruguayan Megalabs, and French firm Sanofi Made with Visme Infographic Maker  

Americas The latest news from pharma and healthcare in Latin America, including funding and logistics challenges in national COVID-19 vaccination programs, a new variant of the virus in Colombia, and the impasse between Pfizer and the Peruvian government.   First Covid-19 Vaccines Are Given in Latin America, But Region Faces Challenges…

Roundup The latest from healthcare and the life sciences in Latin America, including the most recent wave of Indian pharma investment; Argentina’s ongoing struggle with COVID-19; issues around unchecked use of an anti-parasite drug; and the seismic economic and social impact of upcoming cannabis legalisation in Mexico.   Six Indian drug…